A Brief History of Genetic Vaccines by Julie Beal for Activist Post
To help illustrate the long history of DNA vaccine failure, this article will trace the history of clinical trials of genetic HIV vaccines. It’ll also take a look at the development of tests of infection in the 1980s which are being used to stage a fake pandemic in the years 2020 to 2021.
No vaccine can be deemed ‘safe’, and every vaccine is different. However, anyone looking for more information on the potential risks of the coronavirus vaccines should know that almost every aspect of them has been tested. This is important, not only because it casts light on what the coronavirus vaccines contain, but also because it shows just how much effort has gone into them. Essentially, groups like the Pox-Protein Public Private Partnership, set up by the Gates Foundation, NIH, GSK, and others, have been conducting large-scale experiments with genetic vaccines across Africa for years. This was in response to lots of ‘confirmed cases’ of Zika, Ebola, HIV, etc., and means thousands of people have now been dosed with various forms of synthetic DNA and mutant viruses designed and created in a lab.
The Pox-Protein Public-Private Partnership
Some of the biggest trials of genetic vaccines have been for HIV, which the Pox-Protein Public Private Partnership has spent the last ten years trying to get to market, without success. Known as the P5 for short, the group was set up in 2010 by the Bill & Melinda Gates Foundation, the National Institutes of Health, Sanofi Pasteur, GlaxoSmithKline (GSK), the South African Medical Research Council, the HIV Vaccine Trials Network (HVTN), and the US Military HIV Research Program. This was to continue the long-running RV144 trials of recombinant glycoprotein vaccines for HIV which date back to the early 1990s, with the development of AIDSVAX, a vaccine containing the recombinant glycoprotein gp160, which is a small molecular sequence said to be found on the surface of a HIV virus.
In 1993, gp160 was used in a phase I trial, and in 2002, trials of gp120 got to phase 3. However, throughout all the trials, the vaccines have shown only “modest protective efficacy”; namely, by failing to reduce ‘infection’ rates. Another trial was the STEP study (by Merck), which used three chimp ‘Ad5’ viruses that would get people to produce several different HIV proteins, but the study was stopped in 2007 because there were higher rates of HIV infection in the vaccinated group than in the placebo.
The increased rate of HIV infection occurred in men-who-have-sex-with-men who were uncircumcised and/or had pre-existing antibodies to Ad5. This phenomenon is still unexplained.
The HVTN trial, begun in 2009, and sponsored by the NIH, used a vaccine expressing HIV proteins for the ‘prime’, then ‘boosted’ it with a viral vector expressing the same proteins, but the trial was stopped in 2013, because, yet again, “the vaccine regimen did not reduce the rate of HIV infection or mitigate the infection of those volunteers who had acquired HIV while on the trial.”
By this point, the P5 had gotten involved, and in 2015 various new approaches were tried, using viral vectors, proteins, and an adjuvant called MF59, in different combinations. (Note, MF59 is also being added to a number of coronavirus vaccines.) The first jab was a ‘priming’ vaccine (they used ALVAC-HIVby Aventis Pasteur) containing a canarypox virus vector, and the second was a ‘booster’ (AIDSVAX B/E by VaxGen), which contained subunits of the HIV surface glycoprotein gp120. However, after being tested on thousands of people in phase 3 trials across South Africa and Thailand, the trials were declared a failure. As usual, they were plagued with a lack of ‘immunogenicity’ – and adverse eventswere deemed unrelated to the vaccine.中山文香中山文香,凉川绚音凉川绚音,守望人妻守望人妻
Alarmingly, some of the vaccines were found to be contaminated with a kind of bacteria (Mycoplasma hyorhinis), which had come from pigs. In 2015, it was reported that 94 people had been injected with the contaminated vaccine, whilst taking part in a clinical trial for NYVAC-HIV-PT1. The Phase 1 trials took place in Switzerland and the USA (2012-2013). After announcing their latest failure in February (2020), the group are now focusing on the role of the microbiome (i.e. gut health – more on this below).
How did we get here?
Step back in time to 1984, and we find Anthony Fauci taking the helm of the NIH, the same year that HIV was ‘discovered’ by Robert Gallo. Fauci has overseen the agency throughout all of the trials of genetic vaccines, many of which have been initiated and sponsored by the NIH itself. 1984 was a world-changing turning point for the future of vaccines because a new virus called HIV was announced, leading to a change in the definition of both ‘virus’ and ‘infectivity’.